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license (http://creativeand decreased retinal venous blood flow compared with control subjects. We assessed whether these
abnormalities are present in patients with mild cognitive impairment (MCI).
Methods: After the determination of the global clinical dementia rating, 52 subjects (10 AD, 21
MCI, and 21 normal controls) underwent retinal hemodynamic profiling. Blood column diameter,
blood speed, and blood flow were measured in a major temporal retinal vein using retinal laser
Doppler flowmetry. In addition, peripapillary retinal nerve fiber layer (RNFL) thickness was
measured using optical coherence tomography.
Results: Blood column diameter in AD was narrower than in both MCI (P 5 .004) and controls
(P5 .002). However, blood speed in both AD (P5 .024) and MCI (P5 .005) was lower than in con-
trols. As a result, the differences in blood flow between AD and MCI (P 5 .036), AD and controls
(P , .0001), and MCI and controls (P 5 .009) were significant. Although there were no differences
in RNFL thickness among the groups, blood flow was correlated (P 5 .047) with superior RNFL
thickness in the AD group, but not in the MCI (P 5 .40) or control (P 5 .84) groups.
Conclusions: Retinal blood flow in MCI is intermediate between what is measured in control sub-
jects and in AD patients. Our findings suggest that blood flow abnormalities may precede the neuro-
degeneration in AD.
 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Transcranial Doppler ultrasonography [1], single photon
emission computed tomography, and magnetic resonance
imaging (MRI) [2] all demonstrate that cerebral blood flow
is diminished in Alzheimer’s disease (AD). The findings of
diminished blood flow correlate with pathology studies
that show decreased vascular density, tortuous arterioles,
and deposition of excessive collagen in veins and venules
[3,4]. However, there is as yet no consensus on whether
decreased cerebral blood flow is a cause or a consequencethor. Tel.:11-617-573-3670; Fax:11-617-573-3707.
ouis_Pasquale@meei.harvard.edu
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he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).of AD [5]. It has been suggested that impaired nitric oxide
signaling may contribute to the pathology associated with
AD [6,7]. There is evidence that cerebral blood flow is
already decreased in patients with mild cognitive
impairment (MCI) [8], the condition thought to be the prede-
mentia stage of AD. Reduced blood flow compared with
controls in specific regions of the cerebral circulation in
MCI patients has also significantly predicted the progression
to AD in studies with follow-up periods ranging from 2 to
7 years [9–11].
There is evidence that the dysregulation of cerebral blood
flow contributes to the pathogenesis of AD [12]. Resting ce-
rebral blood flow is reduced, and the incremental blood flow
response to neuronal stimulation is attenuated in AD [13].imer’s Association. This is an open access article under the CC BY-NC-ND
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origin, and their microvasculatures share anatomical and
physiological similarities such as the presence of a tightly
controlled blood-tissue barrier and autoregulatory capacity.
Retinal vascular circulatory abnormalities are thus likely
to reflect cerebrovascular pathology [14,15]. Because the
retina is accessible to sensitive, noninvasive optical
diagnostic methodologies, structural and functional
abnormalities analogous to those established to occur in
the brain in AD may also be observed in this tissue [16].
Structural retinal vascular abnormalities in AD patients
include significant thinning of the blood column diameters
in the larger retinal vessels and significantly decreased
vessel density in the retinal microvascular network
compared with controls [17,18]. Only one prior study also
reported reduced retinal blood flow in patients with AD
compared with control subjects [19]. There have not been
any studies of retinal vascular structural abnormalities or
of retinal blood flow abnormalities in patients with MCI.
In this study, we sought to confirm the observations of
altered retinal circulation in AD patients and to determine
whether these abnormalities are also present in patients
with milder clinical symptoms or MCI, that is, earlier in
the course of the disease.2. Methods
2.1. Study subjects
Subjects referred for the study underwent prior cognitive
testing at either the Massachusetts Alzheimer’s Disease
Research Center or the Boston University Alzheimer’s Dis-
ease Center. Subjects with MCI met the 2004 MCI Working
Group Criteria [20] for amnestic MCI and had a global clin-
ical dementia rating (CDR) of 0.5. SubjectswithADmet both
Diagnostic and Statistical Manual of Mental Disorders, 4th
Edition (DSM-IV) [21] diagnostic criteria for dementia and
National Institute of Neurological and Communicative Dis-
orders and Stroke and the Alzheimer’s Disease and Related
DisordersAssociation criteria [22] for probableAD.Subjects
with AD had a global CDR of either 1.0 or 2.0. Control sub-
jects had normal cognition and a global CDR of 0.0. All di-
agnoses were made by a multidisciplinary consensus
diagnostic conference. The Institutional Review Boards at
theMassachusetts Eye andEar Infirmary (MEEI),Massachu-
setts General Hospital, and the Boston University Medical
Center approved this study. Written informed consent to
participate was obtained from each subject before the oph-
thalmoscopic examinations that were performed at the
MEEI. The investigators performing the retinal assessments
were blind to the cognitive status of the subjects.2.2. Study procedures
Each subject received a complete ophthalmic examination
including visual acuity assessment, intraocular pressure (IOP)measurement using Goldmann applanation tonometry (Haag
Streit USA, Mason, OH), slit lamp biomicroscopy, indirect
ophthalmoscopy, and digital fundus photography in both
eyes. We added tropicamide 1% in both eyes for pupillary
dilation. To facilitate the retinal blood flow measurements,
only subjects with refractive error within the range 210 to
110 diopters, no significant cataract or cataract surgery
within the prior 6 months, and pupillary dilation of at least
6 mm after mydriasis were tested. Subjects with a history of
diabetes mellitus or evidence of glaucoma on examination
were excluded from the analysis. Brachial artery blood pres-
sure and pulse rate were measured using a Keller vital signs
monitor (KellerMedical Specialties, Antioch, IL).Mean arte-
rial pressure (MAP) was automatically displayed.2.3. Laser Doppler retinal blood flow measurements
Blood column diameter, centerline blood speed, and
retinal blood flow rate were reliably measured in a major
temporal retinal vein of each subject using a Canon laser
Doppler retinal blood flow instrument (CLBF 100, Canon,
Tokyo, Japan). The basic principles, technical characteris-
tics, and reproducibility of measurements using the instru-
ment have been described previously [23]. The blood flow
rate in units of microliter per minute in a retinal vessel is
determined from simultaneous measurements of the blood
column diameter and the centerline blood velocity. Measure-
ment sites were along relatively straight segments of the
largest temporal vein approximately one disc diameter
away from the optic disc margin. The instrument is equipped
with an internal fixation target and an automatic eye tracking
system that maintains centration of the measuring laser
beam on the target blood vessel to compensate for eye move-
ments. Results are acquired at 50 measurements per second
for 2 seconds. Bilateral measurements were not successful in
all study subjects because of media opacities or the anatom-
ical arrangement of the retinal vessels. Measurements in all
subjects were performed during the midday hours, between
12 p.m. and 4 p.m., by the same experienced examiner
(GTF). Only one eye of each subject was included in the
analysis. If both eyes had reliable measurements, the eye
with the larger diameter temporal retinal vein was desig-
nated as the study eye. The retinal vein with the largest diam-
eter drains the largest retinal area and carries the greatest
fraction of the total retinal blood flow. The blood flow in
this vein is thus representative of the total retinal blood
flow. Veins rather than arteries were chosen for measurement
because of technical reasons. The instrument eye tracking
system performs more efficiently when the target vessel
has a larger diameter and carries deoxygenated blood. The
designated eye was used in all subsequent analyses.2.4. Retinal nerve fiber layer thickness measurements
To quantify retinal neuronal loss due to the pathological
mechanisms associated with AD, peripapillary retinal nerve
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each subject using the Stratus OCT 3000 (Carl Zeiss Medi-
tec, Inc., Dublin, CA). Optical coherence tomography
(OCT) is a noninvasive technique that allows the high-
resolution cross-sectional imaging of the retina. The basic
principles and technical characteristics of the OCT have
been described previously [24,25]. For the RNFL
measurements the standard RNFL thickness circle scan
mode consisting of three circular scans with a diameter of
3.4 mm centered on the optic nerve head was used.
Average overall and quadrant (superior, inferior, temporal
and nasal) RNFL thickness was automatically calculated.
We chose the best quality scan (highest signal strength and
adequate signal-to-noise ratio) for RNFL thickness analysis.
A signal strength of 7 or greater in the study eyewas required
for inclusion in the analysis.2.5. Statistical considerations
Before study inception, we calculated the statistical po-
wer to detect differences in retinal blood flow between the
three study groups (AD, MCI, and controls) using a sample
size of 30 subjects for each group. The results from our
earlier study [19] of retinal blood flow differences between
AD and control subjects were used to provide estimates.
Assuming a two-sided test with a 5 0.05, the estimated po-
wer was .0.99 to detect a 10% difference in the means be-
tween any two groups, 0.89 to detect a difference of 7% in
the means, and 0.62 to detect a difference of 5% in the
means. In this study we thus expected that there would be
excellent power to detect a similar result between AD and
control subjects and good power to detect retinal blood
flow differences between MCI and control subjects where
we hypothesized that the differences would be less striking.
All data were analyzed using the statistical software Stat-
View for Windows, version 5.0 (SAS Institute, Cary, NC).
Between group differences were assessed using the analysis
of variance (ANOVA) with Fisher’s Protected Least
Significant Difference (PLSD) post hoc tests. Stepwise mul-
tiple linear regression analysis was used to determine which
independent variables were significant determinants of the
differences in retinal blood flow measured in study subjects.
Univariate Spearman correlation analysis and linear regres-Table 1
Demographic and physiologic characteristics of study subjects when stratified acc
AD (n 5 10) MCI (n 5 21
Age (yrs) 74.3 6 12.2 74.4 6 10.5
Gender (M/F) 3/7 11/10
MAP (mmHg) 96.7 6 11.5 94.0 6 10.8
BP Meds (Y/N) 6/4 10/11
Pulse (bpm) 70.9 6 11.4 69.6 6 11.3
IOP (mmHg) 15.1 6 3.6 13.8 6 2.7
Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive impairment; M
pressure lowering medications; Y, yes; N, no; bpm, beats per minute; IOP, intraoc
*ANOVA, analysis of variance.sion analysis were used to examine the relationship between
retinal blood flow and global CDR, age, MAP, and RNFL
thickness. Results are expressed as mean 6 standard devia-
tion. All tests were two tailed, and P values less than .05
were considered to be statistically significant.3. Results
A total of 71 subjects were referred for the study. Retinal
blood flow and RNFL thickness measurements were suc-
cessfully obtained in 64 subjects. Of the remaining subjects,
six had a history of type 2 diabetes mellitus, and two had an
evidence of open angle glaucoma on examination. Data from
these subjects were excluded from the analysis because de-
creases in retinal blood flow are known to occur in these con-
ditions [26,27]. In addition, review of the dementia status of
the remaining subjects revealed that elements of vascular
dementia were included in the diagnosis of four patients.
The data from these four patients were also excluded from
the analysis. As a result, data from 52 subjects were used
in the analysis.
Subjects ranged in age from 51 to 90 years
(72.3 6 9.7 years). Eighteen subjects were male and 34
were female. Four subjects were African American and 48
were Caucasian. Data from the right eye were analyzed in
18 subjects, and from the left eye in 34 subjects.
There were no statistically significant differences be-
tween the demographic and physiologic characteristics of
the subjects when stratified according to the dementia status
(Table 1).3.1. Venous diameter, blood speed, and blood flow
according to cognitive status
Venous blood column diameter was 133.86 8.8 mm in 10
subjects with AD (CDR5 1.0 or 2.0), 153.26 17.4 mm in 21
subjects with MCI (CDR5 0.5), and 154.36 18.7 mm in 21
control subjects (CDR 5 0.0) (Fig. 1). The blood column
diameter was significantly lower in AD subjects compared
with the MCI subjects (P 5 .004) and the control subjects
(P 5 .002). The difference in blood column diameter be-
tween the MCI and control subjects was not significant
(P 5 .83).ording to dementia status
) Normal controls (n 5 21) P value*
69.1 6 6.7 .16
4/17 .07
95.1 6 17.8 .88
8/13 .53
69.5 6 9.8 .94
14.4 6 3.0 .52
/F, male/female; MAP, mean brachial arterial pressure; BP Meds, blood
ular pressure.
Fig. 1. Mean values of the retinal venous blood column diameter in subjects
with Alzheimer’s disease (AD), with mild cognitive impairment (MCI), and
in control subjects. Error bars represent one standard deviation. Significance
levels for paired comparisons were determined using Fisher’s Protected
Least Significant Difference (PLSD) tests.
Fig. 3. Mean values of the retinal venous blood flow in subjects with Alz-
heimer’s disease (AD), with mild cognitive impairment (MCI), and in con-
trol subjects. Error bars represent one standard deviation. Significance levels
for paired comparisons were determined using Fisher’s Protected Least Sig-
nificant Difference (PLSD) tests.
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AD, 28.9 6 6.3 mm/s in subjects with MCI, and
36.06 9.3mm/s in control subjects (Fig. 2). The blood speed
was significantly lower in both AD (P5 .024) and MCI sub-
jects (P 5 .005) compared with the blood speed in control
subjects. The difference in blood speed between subjects
with AD and MCI was not significant (P 5 .95).
Venous blood flow was 12.36 2.8 ml/min in subjects with
AD, 16.16 4.4ml/min in subjectswithMCI, and20.06 5.4ml/
min in control subjects (Fig. 3). The blood flow in AD subjects
was significantly lower than in both MCI (P5 .036) and con-Fig. 2. Mean values of the retinal venous blood speed in subjects with Alz-
heimer’s disease (AD), with mild cognitive impairment (MCI), and in con-
trol subjects. Error bars represent one standard deviation. Significance levels
for paired comparisons were determined using Fisher’s Protected Least Sig-
nificant Difference (PLSD) tests.trol subjects (P, .0001). The blood flow inMCI subjects was
also significantly lower than in control subjects (P5 .009).3.2. RNFL thickness according to cognitive status and
relationship to venous blood flow
There were no statistically significant differences be-
tween the RNFL thicknesses measured in the inferior, tem-
poral, or nasal retinal quadrants between subjects with
AD, MCI, and control subjects. P values ranged from 0.38
to 0.98. Superior quadrant RNFL thickness was
108.8 6 13.3 mm in AD subjects, 118.2 6 13.4 mm in
MCI subjects, and 117.7 6 15.2 mm in control subjects. Su-
perior RNFL thickness in AD patients was decreased by
7.6% compared with control subjects (P 5 .109) and by
8.0% compared with patients with MCI (P 5 .088), differ-
ences that were not statistically significant. The 0.4% differ-
ence in superior RNFL thickness between the MCI and
control subjects was also not significant (P 5 .90).
The relationships betweenvenous blood flow and superior
RNFL thickness are illustrated by the correlation plots that
include results from patients with AD in Fig. 4A, from pa-
tients with MCI in Fig. 4B, and from only control subjects
in Fig. 4C. The positive correlation between venous blood
flow and superior RNFL thickness in AD patients was statis-
tically significant (r5 0.66;P5.047). However, there are no
significant correlations between venous blood flow and supe-
rior RNFL thickness inMCI patients (r5 0.19;P5.40) or in
control subjects (rho 5 20.04; P 5 .84).3.3. Determinants of retinal blood flow
Stepwise multiple linear regression analyses were used to
determine which factors were significantly related to the
Fig. 4. Retinal venous blood flow plotted as a function of the thickness of
the peripapillary retinal nerve fiber layer (RNFL) in the superior retinal
quadrant in patients with Alzheimer’s disease (AD) (A) with mild cognitive
impairment (MCI) (B), and in normal control subjects (C). The values of the
Spearman correlation coefficients (rho) and the corresponding P values are
shown.
Table 2
Result of stepwise multiple linear regression analysis of independent factors
significantly related to retinal venous blood flow measured in study subjects
Coefficient P value
CDR 25.29 ,.0001
Age 20.14 .032
MAP 0.11 .015
Abbreviations: CDR, global clinical dementia rating; MAP, mean
brachial arterial pressure.
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In the first analysis, the independent variables were age, sex,
brachial MAP, pulse rate, IOP, average RNFL thickness from
the four retinal quadrants, and global CDR. In an alternate
analysis, the use or nonuse of blood pressure lowering med-ications was considered instead of the actual brachial MAP.
In the optimummodel (Table 2), retinal blood flow decreases
with increasing CDR (P, .0001), increases with increasing
MAP (P 5 .015), and decreases with age (P 5 .032).4. Discussion
The results confirm that retinal venous blood flow in
AD is decreased compared with that in control subjects
[19], and reveal that the same retinal circulatory abnor-
mality is present in patients with MCI. In the prior study
[19], which used the same laser Doppler methodology as
this study, blood flow was decreased by 39.0% in AD pa-
tients compared with control subjects. In this study, blood
flow in the AD patients is decreased by 38.6% compared
with control subjects. The agreement is remarkable and
solidifies the finding of reduced retinal blood flow in
AD. To date, there have been no other studies reporting
retinal blood flow findings in patients with AD.
There have been no prior studies of retinal blood flow
in patients with MCI. In this study, blood flow in the MCI
patients is decreased by 19.4% compared with control
subjects. The magnitude of the decrease in blood flow in
the MCI patients is one-half of the decrease in the AD
patients.
There have been three prior studies of retinal venous
blood column diameters in patients with AD. In the study
[19] that used the same laser Doppler methodology as this
study, the blood column diameter of the major temporal
retinal vein was decreased by 11.2% in patients with
AD compared with that in control subjects. In this study,
the retinal venous blood column diameter is decreased by
13.3%. In another prior study [17], investigators used an
automated retinal photographic technique and an algo-
rithm to estimate the diameters of the central retinal artery
and central retinal vein using the measured diameters of
the six largest branch retinal arteries and six largest
branch retinal veins in patients with AD and in control
subjects. They reported a 4.8% decrease in the estimated
central retinal artery diameter and a 7.1% decrease in
the estimated central vein diameter in the AD patients
compared with controls. More recently, other investigators
[18] also used the same algorithmic retinal photographic
technique and reported a 9.0% decrease in the estimated
central retinal artery diameter and a 9.9% decrease in
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compared with controls. In this study, we directly
measured the blood column diameter of the largest tempo-
ral vein in AD patients and in controls. Our results are
consistent with those obtained using the retinal photo-
graphic method.
There have been no prior studies of retinal vascular
blood column diameter in patients with MCI. In this study,
venous blood column diameter in the largest temporal
retinal vein in the MCI patients (153.2 6 17.4 mm) was
nearly identical to that measured in the control subjects
(154.3 6 18.7 mm). However, the venous blood speed
was 28.9 6 6.3 mm/s in the MCI patients and
36.0 6 9.3 mm/s in the control subjects, a difference of
19.7%. The decrease in blood flow in the MCI patients is
thus accounted for by the decrease in blood speed measured
at the laser Doppler measurement site along the major tem-
poral retinal vein. The decreased blood flow in MCI must
then arise from narrower venules upstream from the mea-
surement site, obstruction of retinal capillaries, retinal arte-
rial constriction, or a combination of these factors.
Cerebral amyloid angiopathy, characterized by amyloid
b (Ab) deposition in the walls of arteries and arterioles
has been well documented in AD [28–31]. It is known
that the intravascular deposition occurs in parallel with
the formation of Ab deposition in the parenchyma [32].
Deposition of collagen fibrils in the walls of capillaries
[33] and veins [34,35] resulting in narrowed lumina and
even occlusion has also been found in AD patients. It is
thus likely that the mechanisms producing decreased
blood column diameter with concomitant reduced blood
flow in the retinal vasculature are analogous to those
that produce the known vascular narrowing and reduced
cerebral blood flow that occurs in AD. It is also
reasonable to speculate that the narrowing of the retinal
venous diameter observed in our study could be related
to an increased venous wall thickness due to collagen
deposition as found in cerebral veins.
It should be noted that although venous blood flow was
decreased in our patients with MCI, venous blood column
diameter in the large retinal veins, unlike in patients with
AD, was not decreased. Our results suggest that retinal
blood flow measurements are more sensitive than retinal
vessel diameter measurements alone when detecting retinal
hemodynamic changes earlier in the disease course of AD;
that is, in MCI. Reduced blood flow compared with con-
trols in specific regions of the cerebral circulation in
MCI patients has significantly predicted the progression
to AD in studies with follow-up periods ranging from 2
to 7 years [9–11]. It would be interesting to determine
whether follow-up studies of retinal blood flow in MCI pa-
tients would also predict the progression to AD.
The most robust outcome of the multiple linear regres-
sion analysis was that retinal venous blood flow decreases
with increasing global CDR, that is, with worsening de-
mentia. However, the analysis also found that bloodflow decreases with increasing subject age. The decrease
of retinal blood flow with aging in healthy subjects be-
tween the ages of 20 and 82 years has been reported in
three studies [36–38]. In these three studies, blood flow
decreased by 6.4%, 7.8%, and 11.2% per decade,
respectively. Thus, both dementia and age contribute to
decreasing blood flow. It should be noted, however, that
the ages of the AD (74.3 6 12.2 years) and MCI
(74.4 6 10.5 years) patients were nearly identical.
The trend toward the thinning of the superior RNFL in
AD reported here is consistent with a prior study [19].
Such results are also consistent with a study that reported
predominantly inferior visual field defects in AD pa-
tients, which correspond structurally to superior RNFL
defects [39]. In our study, superior RNFL thickness
differed by only 0.4% and average RNFL thickness using
results from all four retinal quadrants differed by only
0.6% between MCI and control subjects. Other investiga-
tors who used the same OCT technology and also
excluded patients with diabetes or glaucoma, however,
reported that average RNFL thickness was decreased by
12.6% in 23 MCI subjects compared with 15 control sub-
jects [40]. Surprisingly, those investigators also reported
that average RNFL thickness in AD was nearly identical
to that in MCI, decreasing by 12.7% in AD compared
with control subjects. There is no clear explanation for
the discrepancy between our results showing essentially
no difference in RNFL thickness in MCI compared
with control subjects and the other results showing a sub-
stantial difference in RNFL thickness in MCI compared
with control subjects.
We also found a significant correlation between retinal
venous blood flow and superior RNFL thickness in the
AD patients. In contrast, there was no significant correla-
tion between blood flow and superior RNFL thickness
in the MCI patients or in the control subjects. Our data
in MCI patients (decreased blood flow in the presence
of unchanged RNFL thickness) suggest that blood flow
abnormalities may precede rather than follow neurodegen-
eration in the pathological process that results in AD. This
issue has been the subject of considerable debate [41,42].
Longitudinal follow-up studies of cognitive function,
retinal blood flow, and RNFL thickness in MCI patients
and control subjects should provide answers to this impor-
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Excellence.RESEARCH IN CONTEXT
1. Systematic review: This article reports the results of
a 3-year study entitled “Objective Biomarkers for
Alzheimer’s Disease in the Retina,” which was
funded primarily by the Alzheimer’s Association.
Preliminary findings had shown for the first time
that retinal blood flow was abnormally decreased in
patients with Alzheimer’s disease (AD). The goal
of this study was to determinewhether blood flow de-
creases were already present in patients with mild
cognitive impairment (MCI).
2. Interpretation: The study results show that, as in the
cerebral circulation, blood flow in the retinal circula-
tion is decreased in MCI and further decreased in
AD. Our findings also suggest that blood flow abnor-
malities may precede neurodegeneration in AD.
Because the retina is accessible to sensitive noninva-
sive optical diagnostic methodologies, it is an excel-
lent site for the detection of the earliest structural and
functional abnormalities in AD.
3. Future directions: A means to detect the earliest indi-
cators of progression of MCI to AD is of utmost clin-
ical importance because treatments applied early will
be the most effective at delaying the neurodegenera-
tive process. Monitoring retinal blood flow over time
may provide the means to do this.References
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